ReviewThe AAPS journal2015
Lipid-based drug carriers for prodrugs to enhance drug delivery.
Review in The AAPS journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Cholesterol and Albumin as Key Modulators of ICG Photostability in Aqueous Solution.Molecules (Basel, Switzerland) · 2026Article
- Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2026Review
- Next-Generation Lipid Prodrugs Orally Deliver Tenofovir via Enhanced Chylomicron Incorporation.ACS pharmacology & translational science · 2025Article
- Drug Repurposing for Kala-Azar.Pharmaceutics · 2025Article
- In Vitro and In Vivo Appraisal of Glycerylmonostearate/chitosan Hybrid Nanocapsules As Peroral Delivery System of Simvastatin.AAPS PharmSciTech · 2025Article
- Synthesis of Enantiostructured Triacylglycerol Prodrugs Constituting an Active Drug Located at TerminalMolecules (Basel, Switzerland) · 2025Article
- Synthesis of Enantiostructured Triacylglycerols Possessing a Saturated Fatty Acid, a Polyunsaturated Fatty Acid and an Active Drug Intended as Novel Prodrugs.Molecules (Basel, Switzerland) · 2024Article
- Engineered extracellular vesicles coated with an antimicrobial peptide for advanced control of bacterial sepsis.Journal of extracellular biology · 2024Article
- Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes.Cancer letters · 2023Article
- Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases.Advanced healthcare materials · 2023Review
- Strategies to improve the physicochemical properties of peptide-based drugs.Pharmaceutical research · 2023Review
- Review
- An acyclic phosphonate prodrug of HPMPC is effective against VZV in skin organ culture and mice.Antiviral research · 2022Article
- Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.Journal of nanobiotechnology · 2022Review
- Article
- Lipid-Based Drug Delivery Systems in Regenerative Medicine.Materials (Basel, Switzerland) · 2021Review
- Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles.Pharmaceutical research · 2021Review
- Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.Nature nanotechnology · 2021Article
- Formulation and Applications of Lipid-Based Nanovehicles: Spotlight on Self-emulsifying Systems.Advanced pharmaceutical bulletin · 2021Review
- Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement.Advanced pharmaceutical bulletin · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of lipid drug delivery systems with prodrugs offers several advantages including improved pharmacokinetics, increased absorption, and facilitated targeting. Lipidization and use of lipid carriers can increase the pharmacological half-life of the drug, thus improving pharmacokinetics and allowing less frequent dosing. Lipids also offer advantages such as increased absorption through the intestines for oral drug absorption and to the CNS for brain delivery. Furthermore, the use of lipid delivery systems can enhance drug targeting. Endogenous proteins bind lipids in the blood and carry them to the liver to enable targeting of this organ. Drugs with significant side effects in the stomach can be specifically delivered to enterocytes by exploiting lipases for prodrug activation. Finally, lipids can be used to target the lymphatic system, thus bypassing the liver and avoiding first-pass metabolism. Lymphatic targeting is also important for antiviral drugs in the protection of B and T lymphocytes. In this review, both lipid-drug conjugates and lipid-based carriers will be discussed. An overview, including the chemistry and assembly of the systems, as well as examples from the clinic and in development, will be provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.